Context: Subclinical hypercortisolism (SH) occurs in 5% to 30% of adrenal incidentalomas (AIs). Common screening tests for adrenocorticotropin-independent hypercortisolism have substantial false-positive rates, mandating further time and resource-intensive investigations.
I
ncidentally discovered adrenal lesions [so-called adrenal incidentalomas (AIs)] are a common cause of endocrine referral (1) . Although most are benign and not associated with overt endocrine dysfunction, subtler forms of adrenal hypersecretion (hypercortisolism, hyperaldosteronism, sex-steroid excess, or phaeochromocytoma) have been variably reported in up to 20% to 40% of AIs (2, 3) . The terms subacute autonomous glucocorticoid hypersecretion, subclinical Cushing syndrome, (possible) autonomous cortisol secretion, and subclinical hypercortisolism (SH) are often interchangeably used to denote adrenocorticotropin (ACTH)-independent cortisol secretion from a benign adrenal adenoma or nodular adrenal hyperplasia that is not associated with clinically overt hypercortisolism (2, 4, 5) . Several groups have reported adverse clinical sequelae in individuals with SH, with recent studies highlighting an increase in cardiovascular morbidity and mortality compared with the general population (6) (7) (8) (9) (10) (11) (12) . Although independent medical treatment of cardiovascular risk factors may represent a reasonable long-term management strategy for individuals with SH, recent advances in laparoscopic and retroperitonoscopic adrenalectomy raise the possibility of a potentially curative intervention for a subgroup of patients (13, 14) . A related but frequently underappreciated risk in these patients is chronic hypothalamic-pituitary-adrenal axis suppression, resulting in an impaired or absent stress response to intercurrent illness (7) . Accurate exclusion or confirmation of a diagnosis of SH is therefore a key step in the investigation and management of patients with AIs.
The 1-mg overnight dexamethasone suppression test (ONDST) is often used as a sensitive screening test to exclude SH (1, 4, 15) , but its relatively poor specificity (70% to 80%) results in a significant number of falsepositive tests, requiring further evaluation that is both time and resource intensive (4) . This has led some workers to propose a higher threshold [$5 mcg/dL ($138 nmol/L)] for triggering additional screening/ confirmatory investigations in the context of AI (15) but with the inevitable consequence of failing to diagnose milder cases of SH. Measurement of 24-hour urinary free cortisol (UFC) excretion rates is also potentially problematic with causes of both false-positive (e.g., obesity) and false-negative (e.g., mild hypercortisolism, renal impairment) results recognized (4, 16) . Demonstration of the loss of the normal circadian rhythm of cortisol secretion is considered a sensitive test for the detection of hypercortisolism, but opinions vary as to the thresholds that should be used to optimize detection while minimizing false-positive results; for example, although a sleeping midnight serum cortisol of ,1.8 mcg/dL (,50 nmol/L) effectively excludes Cushing syndrome in the absence of cyclical hypercortisolism, false-positive results are common, especially in patients hospitalized for short periods (,48 hours) (4, (17) (18) (19) . Similarly, late-night salivary cortisol is sensitive for the detection of hypercortisolism but may be falsely elevated in shift workers, smokers, or if there is blood contamination of the sample (4, 20, 21) . Early morning (9 AM) plasma ACTH levels are typically low or suppressed in SH, but there is overlap with ACTH levels seen in healthy individuals, reflecting its pulsatile secretion and short half-life (4, 22) .
Synthesis and secretion of the adrenal androgen dehydroepiandrosterone (DHEA) and its sulfated form, DHEAS, are regulated by pituitary ACTH. Sustained suppression of central ACTH drive therefore leads to a reduction in DHEA and DHEAS levels (23) (24) (25) . However, DHEA has a short half-life (25 minutes) and is secreted in a circadian manner similar to ACTH; hence, the interpretation of a single DHEA measurement is subject to the same caveats as with ACTH. In contrast, DHEAS has a prolonged half-life in serum (10216 hours), with relatively stable levels throughout the day, making it a more attractive marker for the detection of chronically suppressed ACTH (26, 27) . Indeed, the potential utility of DHEAS to reflect ambient ACTH levels over a longer time interval has led to DHEAS being proposed as an indicator of persisting autonomous ACTH secretion in Cushing disease following pituitary surgery (28) and as a possible marker of SH in patients with AI (29) (30) (31) .
We therefore performed a systematic comparison of a single DHEAS measurement at presentation with the current gold-standard 1-mg dexamethasone suppression test for the detection of SH in 185 consecutive individuals with AI referred to the endocrine department of a university hospital. We describe the utility of DHEAS as a sensitive and specific marker of SH within this cohort.
Patients and Method

Patients
The records of 185 consecutive patients with adrenal incidentalomas referred to the Endocrine Department of Cambridge University Hospitals Foundation Trust between January 2006 and April 2013 were reviewed. All patients had undergone standardized clinical, biochemical, and radiological assessments according to an institutional protocol, as part of routine clinical care. We performed a retrospective analysis of this systematically collected data set. Appropriate institutional approval was obtained.
Seventeen patients were excluded on the basis of: (1) concomitant use of drugs influencing glucocorticoid metabolism or secretion, (2) major psychiatric illness or history of excess alcohol intake, or (3) overt clinical features of hypercortisolism. One patient had previously undergone pituitary surgery and was also excluded. All AIs were discovered by computed tomography scanning or magnetic resonance imaging performed for unrelated reasons, and all lesions were .1 cm in diameter. Adrenal adenomas displayed the following radiological features: either #10 HU on unenhanced computed tomography (in which case no further characterization was performed) or .50% absolute washout at 10 minutes (or .60% at 15 minutes) on triple-phase adrenal computed tomography or signal dropout on chemical shift magnetic resonance imaging (32, 33) .
All patients were assessed by 1 of 3 clinicians experienced in the diagnosis and management of Cushing syndrome, and each underwent standardized clinical and biochemical screening at first presentation according to an institutional clinical protocol. This included measurement of plasma metanephrines, 24-hour 
Assays
Biochemical assays were run in a United Kingdom Accreditation Service (http://www.ukas.com/default.asp)-accredited clinical laboratory. External quality assurance for all assays was provided by United Kingdom National External Quality Assessment Service (http://www.ukneqas.org.uk).
DHEAS and ACTH were assayed using a Siemens (Surrey, UK) Immulite 2000 platform with reagents provided by the same manufacturer. DHEAS was analyzed by solid-phase competitive immunoassay. Age-and sex-adjusted reference ranges for DHEAS are provided in Table 1 . ACTH was analyzed by sequential 2 site solid phase chemiluminescent immunoassay.
Aldosterone was measured using solid-phase radioimmunoassay (Coat-A-Count, Siemens, Los Angeles, CA). The laboratory working range was 70 to 3330 pmol/L. Plasma renin was measured using a Diasorin XL (Kent, UK) chemiluminescent immunometric assay. The laboratory working range was 2 to 3000 mIU/mL.
Plasma metanephrines were analyzed using a derivitization enzyme-linked immunosorbent assay provided by Labor Diagnosticka Nord GmbH (Nordhorn, Germany). The laboratory working range was 41 to 2100 pg/mL for metanephrine and 58 to 58,000 pg/mL for normetanephrine.
Urine cortisol was measured by competitive radioimmunoassay using reagents provided by Siemens (Coat-a-Count) or using an in-house liquid chromatography-tandem mass spectrometry method. The laboratory working range was 25 to 1380 nmol/L, and the laboratory reference range for the radioimmunoassay was ,180 nmol/24 h. The mass spectrometric assay was performed using an API 5500 triple quadrupole mass spectrometer (AB Sciex, Warrington, UK) using atmospheric pressure chemical ionization. Deuterated (d4) cortisol was used as an internal standard. Urine samples were mixed with internal standard in 50% methanol/water. Samples were precleaned using a C8 reverse-phase column before high-performance liquid chromatography separation using a pheny-hex column with a Shimadzu (Shimadzu, Milton Keynes, UK) high-performance liquid chromatography system. The laboratory working range was 12 to 2330 nmol/L, and the laboratory reference interval for the liquid chromatography-tandem mass spectrometry method was ,146 nmol/24 h.
Between-batch imprecision was ,10% across the working ranges for all assays.
Statistical analysis
With the exception of age and body mass index, which are reported as mean 6 SD, all data are expressed as medians with interquartile ranges (IQRs). For parametric data, hypothesis testing was performed using an unpaired Student t test. For nonparametric data, statistical analysis was performed using the Mann-Whitney U test.
Receiver operating characteristic (ROC) curves were generated to assess the utility of DHEAS in the diagnosis of SH, using the first randomly sampled DHEAS ratio for each patient included in the study. ROC curves were also generated for the 1-mg overnight dexamethasone suppression test and the original 24-hour UFC measurement.
ROC analysis evaluated the performance of each parameter for the diagnosis of SH against nonfunctioning adrenal adenomas (NFAs). Performance of each screening/diagnostic test is expressed as area under the curve (AUC) with 95% confidence intervals. Data are also presented for sensitivity and specificity for each screening/diagnostic test with 95% confidence intervals. All analyses were performed using SPSS version 21.0 (SPSS, Chicago, IL) or GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA).
Due to the systematic nature of investigation for AI in our institution and robust data collection, there were no missing data for ONDST, LDDST, and UFC or demographic details in the study cohort.
Results
Patient characteristics
As described previously, 18 subjects were excluded from further analyses due to confounding clinical disorders or medication usage. Final diagnoses in the remaining 167 patients were nonfunctioning adrenal adenoma (n = 97), subclinical hypercortisolism (n = 29), phaeochromocytoma (n = 19), adrenal metastasis (n = 8), primary aldosteronism (n = 4), adrenal hemorrhage (n = 2), adrenocortical carcinoma (n = 2), myelolipoma (n = 2), and oncocytoma (n = 1), and 3 subjects had Cushing disease with an adrenal incidentaloma (Supplemental Fig. 1A ). There was no difference in age (NFA, 63. 4 ; P = 0.91) between the NFA and SH subgroups. The age distribution of the cohort as a whole was consistent with other published series (Supplemental Fig. 1B ) (6-11). 23 patients had bilateral adrenal adenomas (16 NFAs and 7 SHs).
DHEAS ratio for the screening and diagnosis of SH
There was a significant difference in the DHEAS ratio between the 2 study groups [median (IQR); 2.62 (1.8 to 5.5) for NFAs vs 1.0 (0.77 to 1.0) for SH; P , 0.0001]. DHEAS ratio was a sensitive and specific test both with respect to screening and diagnosis of SH vs NFA [AUC median (IQR), 0.95 (0.91 to 0.99); P , 0.0001]. Evaluation for SH vs NFA showed that for a DHEAS ratio of 1.12, sensitivity was 100% (median [IQR], 86.2% to 100%) and specificity was 91.9% (median [IQR], 83.9% to 96.7%) (Fig. 1) . This finding was consistent in a subgroup analysis of patients with bilateral adrenal adenomas (Supplemental Fig. 2A ). In fact, DHEAS ratio also performed well as a sensitive and a specific test for the diagnosis of SH against all other causes of adrenal lesions within this cohort, as all other non-SH causes of adrenal nodules returned a DHEAS ratio .1.12. Included in this, a low DHEAS ratio also differentiated between ACTH-independent and ACTH-dependent hypercortisolemia in the presence of an adrenal lesion (Supplemental Fig. 3 ).
1-mg Dexamethasone suppression test for the screening and diagnosis of SH
There was a significant difference between the 2 study groups with respect to post-1-mg dexamethasone cortisol levels: median (IQR) of 1. (Fig. 2) . A postdexamethasone value of 1.9 mcg/dL (53 nmol/L) yielded a sensitivity of .99% (IQR, 87.2% to 100%) and a specificity of 82.9% (IQR, 73.4% to 90.1%). As a diagnostic test, a value of 4.0 mcg/dL (109 nmol/L) had a sensitivity of 55.5% (IQR, 35.3% to 74.5%) with a specificity of .99% (IQR, 95.9% to 100%). A postdexamethasone cortisol of 2.1 mcg/dL (58.5 nmol/L) gave the best overall test performance: sensitivity of 92.5% (IQR, 75.7% to 99.0%) and specificity of 88.6% (IQR, 80.1% to 94.4%). Findings in those with bilateral adrenal adenomas were largely consistent with this ( Supplemental  Fig. 2B ). The 1-mg overnight dexamethasone suppression test did not differentiate between SH and other causes of hypercortisolism such as ACTH-mediated or adrenocortical carcinoma.
24-Hour UFC for the screening and diagnosis of SH
For the purpose of analyses, a UFC ratio was calculated by dividing the measured 24-hour UFC by the upper limit of the reference range. There was a significant difference in the UFC ratio between the 2 study groups: median (IQR) of 0.74 (0.46 to 1.16) for NFAs vs 1.3 (0.95 to 1.84) for SH (P , 0.0001) (Fig. 3) . However, UFC performed relatively poorly both as a screening test and as a diagnostic test for SH vs NFA [AUC median (IQR), press.endocrine.org/journal/jcem0.77 (0.67 to 0.87); P , 0.01], and this pattern held true for bilateral adenomas (Supplemental Fig. 2C ). A ratio of 1.01 gave a sensitivity of 69% (IQR, 48.2% to 85.7%) and a specificity of 67% (IQR, 55.5% to 78.2%). A ratio of 0.47 gave a sensitivity of 100% (IQR, 86.8% to 100%) but a specificity of 25.3% (IQR, 15.8% to 37.1%), whereas a ratio of 2.1 gave a specificity of 100% (IQR, 94.9% to 100%) but a sensitivity of just 19.2% (IQR, 6.6% to 39.4%). Therefore, although UFC did not perform well as a screening test, a value greater than twice the upper limit of the reference range performed well as a confirmatory test (Fig. 3) .
Discussion
In this study, we have robustly evaluated the diagnostic utility of a single DHEAS measurement as a sensitive and specific marker of SH in adrenal incidentalomas, using a complete and systematically collected data set. Consecutive patients referred to our service were investigated using widely accepted screening and confirmatory tests (4) . For every patient, we also calculated a ratio of measured DHEAS to the age-and sex-specific lower reference interval. Using this approach, DHEAS ratio performed well as a screening test for SH, with a threshold of #1.12 demonstrating a sensitivity of .99% while showing higher specificity than the ONDST (91% vs 86%, respectively) ( Figs. 1 and 2) . Moreover, DHEAS ratio reliably differentiated between SH and non-SH etiologies of adrenal nodules within our cohort (Supplemental Fig. 3 ). Our findings lend important support to previous proposals and guidelines, which have observed that a low or suppressed DHEAS level should be considered a potential indicator of SH in the context of AI (29-31). Yener and colleagues (29) have also explored the association between low DHEAS levels and SH, noting that an ageunadjusted DHEAS threshold of 40.0 mcg/dL provided a sensitivity of 68% and a specificity of 75% for the diagnosis of SH. In the study reported here, we have demonstrated a higher sensitivity and specificity for low DHEAS in the diagnosis of SH. This may be explained by some important differences in study design. First, rather than adopting a higher ONDST threshold [3.0 mcg/dL (83 nmol/L)] as a confirmatory test for SH, we have used the diagnostic criteria recommended in the Endocrine Society Clinical Practice Guidelines (4), which include the LDDST as a "gold-standard" confirmatory test. In our hands, compared with the LDDST, the higher ONDST threshold of 3.0 mcg/dL (83 nmol/L) performed less well as a confirmatory test for SH, returning a sensitivity of 85% and specificity of 95%. Second, we have accounted for the expected age-related decline and sex-related differences in DHEAS by calculating a sex-and age-adjusted DHEAS ratio based on locally validated reference ranges rather than using absolute DHEAS values (Table 1) . Although a previous report by Bencsik and colleagues (34) suggested that DHEAS may not be a useful indicator of hormonal activity in AI, the main focus of this study was to explore the potential for DHEAS to discriminate benign from malignant AI. Moreover, the analysis was restricted to only a small number of histologically confirmed cases (thus introducing potential selection bias). Importantly, the authors noted that DHEAS measurement may have a role once the cortical origin and benign feature of the tumor has been confirmed.
In this study, we used robust criteria for the diagnosis of SH across multiple testing modalities, which allowed us to also examine the performance of investigations that are commonly used to detect/exclude hypercortisolism. The ONDST performed well as a screening test for SH. The traditional cortisol threshold of $1.8 mcg/dL ($50 nmol/L) yielded a sensitivity of .99% and a specificity of 81%, consistent with previous findings for this test (Fig. 2) (4) . The higher suggested cutoff value for cortisol of $5 mcg/dL (.138 nmol/L) postdexamethasone provided a specific test (.99%) but at the cost of a low sensitivity of 41%, which would have missed the majority of subsequently diagnosed SH within this cohort. In our hands, the lowest cutoff cortisol value that produced a specificity of .99% was 109 nmol/L. However, this was associated with lower sensitivity (56%) and hence performed poorly as a screening test. As anticipated, the ONDST did not differentiate between ACTH-dependent and ACTH-independent forms of hypercortisolemia. Accordingly, we support the traditional cortisol threshold of $1.8 mcg/dL ($50 nmol/L) in the ONDST as the trigger for further confirmatory testing as recommended in the Endocrine Society and European Society guidelines (4) .
The utility of UFC in the diagnosis of SH and in the broader context of Cushing syndrome has long been debated. There are numerous pitfalls associated with this test. Urine collection over a 24-hour period is not always convenient for the patient, and it is often difficult to obtain a complete sample in the clinic setting. Several studies have shown that 24-hour UFC measurement performs poorly overall both as a screening and a diagnostic test, particularly if reliance is placed on a single measurement (20) . Within our cohort, 24-hour UFC (measured on 2 occasions with the highest value used for subsequent analyses) demonstrated a low sensitivity (67%) and specificity (69%), although values $2 times the upper limit of the reference range carried a specificity of .99% but a sensitivity of only 25% (Fig. 3) . It is important to note, however, that we used a univariate UFC measurement rather than the multianalyte, steroid metabolomic profiling that is increasingly available, with more recent data suggesting superior sensitivity and specificity of urinary steroid metabolomics for the differential diagnosis of steroid excess in the context of adrenal disease (35) .
In the setting of SH, ACTH levels are typically suppressed, and we also observed this, with all affected patients returning levels ,10 ng/L (,2.2 pmol/L). However, measurement of ACTH in the clinical setting carries multiple sampling challenges and can produce falsepositive results when sampled under nonideal circumstances, reflecting the short half-life, pulsatile secretion, and diurnal variability of ACTH release (4) .
Measurement of DHEAS also offers some other potential advantages when screening in AI: first, it allows detection of tumors that are cosecretory (and therefore suspicious for malignancy), and second, it has recently been recognized that some cases of congenital adrenal hyperplasia may present with AI, although we did not identify any such cases in our cohort (36) .
It is important to note, however, that the reliability of low or suppressed DHEAS as a marker for SH may be limited under certain circumstances (e.g., when there is preexisting ACTH suppression in the context of chronic glucocorticoid or opioid use, pituitary disease, or hypothalamic dysfunction). Under these circumstances, a falsepositive result may be obtained (37) . However, each of the existing screening tests has well-recognized limitations and pitfalls and also require specific sampling conditions. Our study has other potential limitations. The reported data are representative of a patient population attending a single center, using a single platform for DHEAS measurement. Multicenter studies and/or meta-analyses, specifically investigating the use of the DHEAS ratio reported here as a screening test for SH in the context of AI, will be required to support and validate our findings, across patient populations, using different DHEAS assays. It will also be important to validate the utility of the DHEAS ratio alone or in combination with the ONDST (at differing threshold values) for confirming or excluding SH without the need to progress to more expensive, time-consuming investigations.
Finally, low DHEAS has also been directly linked with increased cardiovascular risk (38) , and it is interesting to speculate that undiagnosed SH may underlie this association given the recent demonstration that SH is associated with excess cardiovascular mortality (7, 10, 39) .
In conclusion, our data support the use of an ageadjusted DHEAS ratio as a sensitive and specific screening test for SH in patients with incidentally detected adrenal incidentalomas. Pending further studies, we suggest that the identification of a low or suppressed DHEAS level in a patient with AI should trigger more detailed assessment for SH.
